Corrigendum to “Newcastle disease virus vectored Nipah encephalitis vaccines induce B and T cell responses in mice and long-lasting neutralizing antibodies in pigs” [Virology 432 (2012) 327–335, (Virology (2012) 432 (327-335) (S0042682212002863), (10.1016/j.virol.2012.06.001));Newcastle disease virus-vectored Nipah encephalitis vaccines induce B and T cell responses in mice and long-lasting neutralizing antibodies in pigs

Virology

Volumn 432, Issue 2, 2012, Pages 327-335

  Kong, Dongni ^a,b   Wen, Zhiyuan ^a   Su, Hua ^a   Ge, Jinying ^a   Chen, Weiye ^a   Wang, Xijun ^a   Wu, Chao ^a   Yang, Chinglai ^b   Chen, Hualan ^a   Bu, Zhigao ^a  

^a INSTITUTE OF PLANT PROTECTION   (China)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Glycoprotein; Nipah encephalitis virus; Recombinant Newcastle disease virus; Vaccine

Indexed keywords

NEUTRALIZING ANTIBODY; VIRUS FUSION PROTEIN; VIRUS GLYCOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOGENICITY; MIXED INFECTION; MOUSE; NEWCASTLE DISEASE PARAMYXOVIRUS; NIPAH VIRUS; NIPAH VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; SYNCYTIUM; T LYMPHOCYTE; VIROGENESIS;

ANIMALIA; MAMMALIA; MUS; NEWCASTLE DISEASE VIRUS; NIPAH VIRUS; PARAMYXOVIRIDAE; SUIDAE;

EID: 84865305125     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2022.07.001     Document Type: Erratum

References (41)

1. Alexander D.J. Newcastle Disease 1989, American Association for Avian Pathologists, Kennett Square, PA.
2. Alexander D.J. Newcastle Disease and Other Avian Paramyxoviridae Infections 1997, Iowa State University Press, Ames.
3. Anonymous Nipah outbreak in Faridpur District, Bangladesh, 2010. Health Sci. Bull. 2010, 8:6-11.
4. Anonymous Nipah virus encephalitis deaths rise to 21 2011.
5. Anonymous, 2012. BANGLADESH: Outbreak of deadly Nipah virus. IRIN.
6. Bukreyev A., Collins P.L. Newcastle disease virus as a vaccine vector for humans. Curr. Opin. Mol. Ther. 2008, 10:46-55.
7. Bukreyev A., Skiadopoulos M.H., Murphy B.R., Collins P.L. Nonsegmented negative-strand viruses as vaccine vectors. J. Virol. 2006, 80:10293-10306.
8. Chen W., Hu S., Qu L., Hu Q., Zhang Q., Zhi H., Huang K., Bu Z. A goat poxvirus-vectored peste-des-petits-ruminants vaccine induces long-lasting neutralization antibody to high levels in goats and sheep. Vaccine 2010, 28:4742-4750.
9. DiNapoli J.M., Nayak B., Yang L., Finneyfrock B.W., Cook A., Andersen H., Torres-Velez F., Murphy B.R., Samal S.K., Collins P.L., Bukreyev A. Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys. J. Virol. 2010, 84:1489-1503.
10. DiNapoli J.M., Yang L., Samal S.K., Murphy B.R., Collins P.L., Bukreyev A. Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody response. Vaccine 2010, 29:17-25.
11. Ge J., Deng G., Wen Z., Tian G., Wang Y., Shi J., Wang X., Li Y., Hu S., Jiang Y., Yang C., Yu K., Bu Z., Chen H. Newcastle disease virus-based live attenuated vaccine completely protects chickens and mice from lethal challenge of homologous and heterologous H5N1 avian influenza viruses. J. Virol. 2007, 81:150-158.
12. Ge J., Tian G., Zeng X., Jiang Y., Chen H., Bua Z. Generation and evaluation of a Newcastle disease virus-based H9 avian influenza live vaccine. Avian Dis. 2010, 54:294-296.
13. Guillaume V., Contamin H., Loth P., Georges-Courbot M.C., Lefeuvre A., Marianneau P., Chua K.B., Lam S.K., Buckland R., Deubel V., Wild T.F. Nipah virus: vaccination and passive protection studies in a hamster model. J. Virol. 2004, 78:834-840.
14. Halpin K., Hyatt A.D., Fogarty R., Middleton D., Bingham J., Epstein J.H., Rahman S.A., Hughes T., Smith C., Field H.E., Daszak P., The H. Pteropid Bats are Confirmed as the Reservoir Hosts of Henipaviruses: A Comprehensive Experimental Study of Virus Transmission. Am. J. Trop. Med. Hyg. 2011, 85:946-951.
15. Hsu V.P., Hossain M.J., Parashar U.D., Ali M.M., Ksiazek T.G., Kuzmin I., Niezgoda M., Rupprecht C., Bresee J., Breiman R.F. Nipah virus encephalitis reemergence, Bangladesh. Emerg. Infect. Dis. 2004, 10:2082-2087.
16. Ito H., Watanabe S., Takada A., Kawaoka Y. Ebola virus glycoprotein: proteolytic processing, acylation, cell tropism, and detection of neutralizing antibodies. J. Virol. 2001, 75:1576-1580.
17. Khattar S.K., Collins P.L., Samal S.K. Immunization of cattle with recombinant Newcastle disease virus expressing bovine herpesvirus-1 (BHV-1) glycoprotein D induces mucosal and serum antibody responses and provides partial protection against BHV-1. Vaccine 2010, 28:3159-3170.
18. Kortekaas J., de Boer S.M., Kant J., Vloet R.P., Antonis A.F., Moormann R.J. Rift Valley fever virus immunity provided by a paramyxovirus vaccine vector. Vaccine 2010, 28:4394-4401.
19. Lo M.K., Rota P.A. The emergence of Nipah virus, a highly pathogenic paramyxovirus. J. Clin. Virol. 2008, 43:396-400.
20. Luby S.P., Rahman M., Hossain M.J., Blum L.S., Husain M.M., Gurley E., Khan R., Ahmed B.N., Rahman S., Nahar N., Kenah E., Comer J.A., Ksiazek T.G. Foodborne transmission of Nipah virus, Bangladesh. Emerg. Infect. Dis. 2006, 12:1888-1894.
21. Mathew A., Terajima M., West K., Green S., Rothman A.L., Ennis F.A., Kennedy J.S. Identification of murine poxvirus-specific CD8+ CTL epitopes with distinct functional profiles. J. Immunol. 2005, 174:2212-2219.
22. McEachern J.A., Bingham J., Crameri G., Green D.J., Hancock T.J., Middleton D., Feng Y.R., Broder C.C., Wang L.F., Bossart K.N. A recombinant subunit vaccine formulation protects against lethal Nipah virus challenge in cats. Vaccine 2008, 26:3842-3852.
23. Mungall B.A., Middleton D., Crameri G., Bingham J., Halpin K., Russell G., Green D., McEachern J., Pritchard L.I., Eaton B.T., Wang L.F., Bossart K.N., Broder C.C. Feline model of acute nipah virus infection and protection with a soluble glycoprotein-based subunit vaccine. J. Virol. 2006, 80:12293-12302.
24. Ogino M., Ebihara H., Lee B.H., Araki K., Lundkvist A., Kawaoka Y., Yoshimatsu K., Arikawa J. Use of vesicular stomatitis virus pseudotypes bearing hantaan or seoul virus envelope proteins in a rapid and safe neutralization test. Clin. Diagn. Lab Immunol. 2003, 10:154-160.
25. OIE Manual of Diagnostic Tests and Vaccines for Terrestrial Animals 2011 2011, Office International des Epizooties, Paris.
26. Orvell C., Norrby E. Immunologic properties of purified Sendai virus glycoproteins. J. Immunol. 1977, 119:1882-1887.
27. Pallister J., Middleton D., Wang L.F., Klein R., Haining J., Robinson R., Yamada M., White J., Payne J., Feng Y.R., Chan Y.P., Broder C.C. A recombinant Hendra virus G glycoprotein-based subunit vaccine protects ferrets from lethal Hendra virus challenge. Vaccine 2011, 29:5623-5630.
28. Panda A., Huang Z., Elankumaran S., Rockemann D.D., Samal S.K. Role of fusion protein cleavage site in the virulence of Newcastle disease virus. Microb. Pathog. 2004, 36:1-10.
29. Peeters B.P., de Leeuw O.S., Koch G., Gielkens A.L. Rescue of Newcastle disease virus from cloned cDNA: evidence that cleavability of the fusion protein is a major determinant for virulence. J. Virol. 1999, 73:5001-5009.
30. Reed L.J., Muench H. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 1938, 27.
31. Seto J.T., Becht H., Rott R. Effect of specific antibodies on biological functions of the envelope components of Newcastle disease virus. Virology 1974, 61:354-360.
32. Song G.Y., Srivastava T., Ishizaki H., Lacey S.F., Diamond D.J., Ellenhorn J.D. Recombinant modified vaccinia virus ankara (MVA) expressing wild-type human p53 induces specific antitumor CTL expansion. Cancer Invest. 2011, 29:501-510.
33. Takada A., Robison C., Goto H., Sanchez A., Murti K.G., Whitt M.A., Kawaoka Y. A system for functional analysis of Ebola virus glycoprotein. Proc. Nat. Acad. Sci., USA 1997, 94:14764-14769.
34. Tamin A., Harcourt B.H., Lo M.K., Roth J.A., Wolf M.C., Lee B., Weingartl H., Audonnet J.C., Bellini W.J., Rota P.A. Development of a neutralization assay for Nipah virus using pseudotype particles. J. Virol. Methods 2009, 160:1-6.
35. Umino Y., Kohama T., Kohase M., Sugiura A., Klenk H.D., Rott R. Biological functions of monospecific antibodies to envelope glycoproteins of Newcastle disease virus. Arch Virol. 1984, 81:53-65.
36. Wacharapluesadee S., Boongird K., Wanghongsa S., Ratanasetyuth N., Supavonwong P., Saengsen D., Gongal G.N., Hemachudha T. A longitudinal study of the prevalence of Nipah virus in Pteropus lylei bats in Thailand: evidence for seasonal preference in disease transmission. Vector Borne Zoonotic Dis. 2010, 10:183-190.
37. Wang X., Ge J., Hu S., Wang Q., Wen Z., Chen H., Bu Z. Efficacy of DNA immunization with F and G protein genes of Nipah virus. Ann. N. Y. Acad. Sci. 2006, 1081:243-245.
38. Wang Z., La Rosa C., Lacey S.F., Maas R., Mekhoubad S., Britt W.J., Diamond D.J. Attenuated poxvirus expressing three immunodominant CMV antigens as a vaccine strategy for CMV infection. J. Clin. Virol. 2006, 35:324-331.
39. Weingartl H.M., Berhane Y., Caswell J.L., Loosmore S., Audonnet J.C., Roth J.A., Czub M. Recombinant nipah virus vaccines protect pigs against challenge. J. Virol. 2006, 80:7929-7938.
40. Wen Z., Ye L., Gao Y., Pan L., Dong K., Bu Z., Compans R.W., Yang C. Immunization by influenza virus-like particles protects aged mice against lethal influenza virus challenge. Antiviral Res. 2009, 84:215-224.
41. Ye L., Bu Z., Vzorov A., Taylor D., Compans R.W., Yang C. Surface stability and immunogenicity of the human immunodeficiency virus envelope glycoprotein: role of the cytoplasmic domain. J. Virol. 2004, 78:13409-13419.